DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zometa (Zoledronic Acid) - Published Studies

 
 



Zometa Related Published Studies

Well-designed clinical trials related to Zometa (Zoledronic Acid)

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. [2014]

Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams. [2013]

Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer. [2013]

Fracture risk and zoledronic acid therapy in men with osteoporosis. [2012]

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. [2012]

Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. [2012]

Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis. [2012]

Once-Yearly Zoledronic Acid in Older Men Compared with Women with Recent Hip Fracture. [2011.11]

Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. [2011.10.29]

Breast-cancer adjuvant therapy with zoledronic acid. [2011.10.13]

Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial. [2011.09]

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. [2011.08]

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. [2011.07]

The effect of zoledronic acid on the clinical resolution of Charcot neuroarthropathy: a pilot randomized controlled trial. [2011.07]

Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women. [2011.07]

Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. [2011.06]

Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study. [2011.06]

Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial. [2011.05]

The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis. [2011.05]

Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases. [2011.04]

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. [2011.03.20]

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. [2011.03.05]

Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United kingdom. [2011.03]

Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. [2011.03]

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. [2011.03]

Results of a multicenter open-label randomized trial evaluating infusion duration of zoledronic acid in multiple myeloma patients (the ZMAX trial). [2011.01]

Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01). [2011.01]

Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury. [2011.01]

Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and the Netherlands. [2011]

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. [2011]

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. [2010.12.11]

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. [2010.12.10]

Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer. [2010.12.01]

Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance. [2010.12]

Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. [2010.11]

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. [2010.11]

Zoledronic acid for the treatment of osteopenia in pediatric Crohn's disease. [2010.10]

Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. [2010.10]

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [(1-34)rhPTH] in postmenopausal osteoporosis. [2010.09.02]

Characterization of and risk factors for the acute-phase response after zoledronic acid. [2010.09]

A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. [2010.08]

Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. [2010.07]

Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect. [2010.06.15]

Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study. [2010.06]

Long term zoledronic acid during androgen blockade for prostate cancer. [2010.06]

Zoledronic Acid Treatment of Osteoporosis: Effects in Men. [2010.05.24]

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. [2010.05]

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. [2010.03.30]

Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis. [2010.03]

A single dose zoledronic acid enhances pin fixation in high tibial osteotomy using the hemicallotasis technique. A double-blind placebo controlled randomized study in 46 patients. [2010.03]

Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer. [2010.03]

Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. [2010.02]

Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. [2010.02]

Potential mediators of the mortality reduction with zoledronic acid after hip fracture. [2010.01]

Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect. [2010]

Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies. [2010]

Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. [2009.11]

Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. [2009.11]

Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. [2009.10.03]

Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. [2009.10]

Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma. [2009.08.01]

Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. [2009.07]

Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. [2009.05]

Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. [2009.05]

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. [2009.04.11]

Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. [2009.03.13]

Endocrine therapy plus zoledronic acid in premenopausal breast cancer. [2009.02.12]

The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial. [2009.02]

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. [2008.10.01]

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. [2008.09]

Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. [2008.09]

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases. [2008.06.03]

Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. [2008.05]

Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study. [2008.03.31]

Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. [2008.01]

Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. [2008.01]

Zoledronic acid and clinical fractures and mortality after hip fracture. [2007.11.01]

Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression. [2007.11]

Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. [2007.09.26]

Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. [2007.09]

Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. [2007.07]

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. [2007.05.03]

Treatment with Zoledronic Acid Ameliorates Negative Geometric Changes in the Proximal Femur following Acute Spinal Cord Injury. [2007.05]

Treatment with Zoledronic Acid Ameliorates Negative Geometric Changes in the Proximal Femur following Acute Spinal Cord Injury. [2007.04.07]

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. [2007.03.20]

Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. [2007.03.01]

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. [2007.03.01]

The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. [2007.03]

Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. [2007.01]

Dose Dense (CEOP-14) vs Dose Dense and Rituximab (CEOP-14 +R) in High-Risk Diffuse Large Cell Lymphoma. [2007]

Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture. [2007]

A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia. [2006.09]

Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. [2006.09]

Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. [2006.09]

Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. [2006.08.01]

Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. [2006.05]

Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. [2006.02.21]

A prospective randomized controlled clinical trial of zoledronic acid for bone metastases. [2006.01]

Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. [2005.09.01]

Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. [2005.06]

Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. [2005.05.23]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014